Table C3

KQ1: Epoetin versus Control, Study Characteristics, Part II

study authorn randomizedcancer detailscancer categorytherapyHb eligibility criteriaHb base- line EPO arm [mean g/dl (SD)]Control arm mean baseline HB (SD)Hb categoryAGE; EPO arm, as reported (mean, SD) range if not reported otherwiseAGE; control arm, as reported (mean or median, SD), rangeage category (children, adults, elderly (>65)
Aravantinos 2003 47ovarian, lung, stomach, othersolidPlatinum based chemotherapyHb <10.5 g/dL9.8 (+/−0.5)9.32 (+/−0.8)1059 (18–76)64 (23–75)adults
Bamias 2003 144ovarian, NSCLC, SCLC, othersolidPlatinum based chemotherapyHb <13 g/dL11.5 (range 11.1, 11.9)11.5 (range 11.2, 11.8)10–1260 (18–77)62 (19–80)adults
Boogaerts 2003, Coiffier 2001262MM, NHL, CLL, Ovarian, bone, GI, respir, othermixedChemotherapy, platinum & non platinum, details not reported but interpreted as such as some solid cancers which are usually treated with platinum are includedHb ≤ 11 g/dl9.0 (range 5–13)9.2 (range 5–12)1062 (24–68)62 (24–85)adults
Carabantes 1999 35SCLC, ovariansolidPlatinum based chemotherapyHb ≤ 11.5 g/dl10.5 (+/−0.8)10.5 (+/−0.8)10–12NRNRadults
Cascinu 1994 100stomach, ovarian, melanoma, head neck, lung, breastsolidPlatinum based chemotherapy, some, additional radiotherapy, categorized as chemo-platinum allHb ≤9 g/dl8.63 (+/−0.62)8.73 (+/−0.52)10median 58 (44–72)median 57 (45–68)adults
Case 1993 157solid and hemato-logical tumorsmixedChemotherapy without platinumHb ≤ 10.5 g/dl9.29 (SD 1.14)9.57 (SD 1.04)1064 (27–92)64 (30–88)adults
Cazzola 1995 c146MM, NHLhemato- logicalChemotherapy without platinum, some (22%) patients did not receive chemotherapy, categorized as platinum free chemotherapyHb ≤ 11 g/dl
INDEPENDENT OF TRANSFUSION
c: 9.4 (SD 1.9); d: 9.4 (SD 1.0)9.5 (SD 1.1)10c: median 31 (42–85); d: median 63 (28–80)median 68 (28–82)adults
Chang 2005 354Breast cancer, stage I–IVsolidChemotherapy without platinumHb <12g/dL11.2 (SD 0.9)11.3 (SD 0.8)10–1250.4 (SD 11.1, R 27–78)50.1 (SD 10, R 31–85)adults
Dammacco 2001 145MM, NHLhemato- logicalChemotherapy, platinum & non platinumHb ≤ 10 g/dl8.67 (SD 0.9)8.34 (SD 1.4)1060.6 (SD 8.3), range 39–7465 (SD 8.8), range 47–85adults
Del Mastro 1997 62breast, stage IIsolidChemotherapy without platinumHb ≥12g/dL13.00 (0.7)13.1 (0.6)12median 54 (31–66)median 56 (29–68)adults
Dunphy 1999 30head neck, SCLC, stage III/IVsolidPlatinum based chemotherapyNR14.1 (2.1)14.1 (1.6)12median 59 (42–76)median 67 (32–82)adults
EPO-CAN-15106limited disease SCLCsolidPlatinum based chemotherapy plus radiotherapy, categorized as chemo_radioNRNRNRNR (no assumption possible)NRNRadults
EPO-CAN-2066advanced SCLCsolidRadiotherapy +/− non platinum based chemotherapy, categorized as chemo-radiotherapy onlyHb ≤ 12 g/dlNRNRNR (no assumption possible)NRNRadults
EPO-GBR-7301head and neck, stage I’–IVsolidRadiotherapyHb ≤ 15 g/dl13.4 (SD 1.2)13.5 (SD 1.3)1259.8 (SD 10.8)60.2 (SD 10.6)adults
GOG-0191113cervix carcinomasolidPlatinum based chemotherapy plus radiotherapy, categorized as chemo_radioHb ≤ 14 g/dlNRNRNR (no assumption possible)NRNRadults
Henke 2003 351advanced (stage III, IV) head and necksolidRadiotherapy after surgical resection, 22% (78/351) of patients radiotherapy only<13 g/dL (men), <12 g/dL (women)median 11.7 (8.5 –14.4)median 11.8 (6.9 – 14.6)10–12median 58 (25–81)median 57 (36–87)adults
Henry 1995 132solid and hematological tumorsmixedPlatinum based chemotherapyHb ≤ 10.5 g/dl9.68 (SD 1.28)9.27 (SD 1.49)1060 (20–84)60 (34–83)*adults
Henze 2002 232ALL (37%) and non-ALL malignanciesmixedChemotherapy, some non-ALL patients underwent also surgery, categorized as unclearNRNRNRNR (no assumption possible)NRNRchildren
Huddart 2002 90solid tumours, no details givensolidPlatinum based chemotherapyHb <10.5 g/dLNRNRNR (no assumption possible)NRNRadults
Iconomou 2003 122lung, breast, colorectal, ovarian, unknown primary, kidney, stomach, othersolidChemotherapy, platinum & non platinum (51/122 (42%) received platinum)Hb ≤ 11.0g/dL10.1 (+/−SD 0.6)10.1 (+/−SD 0.4)10–1260.6 (SD 10.7), range 33 – 8562.6 (SD 10.3), range 34–80adults
INT-1246ovariansolidPlatinum-based chemotherapyHb ≤ 11 g/dlNRNRNR (no assumption possible)NRNRadults
INT-3201mixedmixedChemotherapy unclearHb ≤ 12 g/dlNRNRNR (no assumption possible)NRNRadults
Janinis 2003 372solid and hematological malignanciesmixedChemotherapy, platinum & non platinum (129/372 (35%) received platinum)Hb ≤ 11.0 g/dLmedian 10.5median 10.510–12NRNRadults
Kunikane 2001 a, b72SCLCsolidPlatinum based chemotherapyHb 9–13 g/dla: 12.3 (SD 1.2), b: 12.3 (SD 1.4)12.0 (SD 0.9)12a: 62.7 (SD 8.7), b: 62.7 (SD 4.8)59.5 (SD 9.9)adults
Kurz 1997 35solid tumours; ovarian, uterus, cervixsolidPlatinum based chemotherapy, 6/35 (17%) did not receive platinum, categorized as platinumHb ≤ 11 g/dl9.88 (SD 0.8)9.85 (SD 0.6)1054.4 (SD 9.7)52.7 (SD 7.5)adults
Leyland-Jones 2003 939metastatic breast cancersolidChemotherapy without platinumHb 13 g/dL, no upper of lower limit on Hb for inclusionmedian 12.8median 12.81255.8 (SD 11.13)55.1 (SD 10.49)adults
Littlewood 2001 375NHL, MM, breast, HD, CLL, GI, othermixedChemotherapy without platinumHb ≤10.5 g/dl OR
10.5–12
AND decrease of ≥1.5 g/dL per cycle
9.9 (SD 1.13)9.7 (SD 1.13)1058.3 (SD 14.8), range 18.7–84.959.5 (SD 13.9), range 21.1–88.6adults
Machtay 2004 148head and neck non-metastatic, not resectedsolidRadiotherapy, advanced stages received in addition platinum based chemotherapy, categorized as radiotherapyHb 9–13.5 g/dL (men), 9–12.5 g/dL (women)12.012.212NRNRadults
N93-004224SCLC, limited and extended diseasesolidPlatinum based chemotherapyHb ≤ 14 g/dlNRNRNR (no assumption possible)NRNRadults
Oberhoff 1998 218solid tumours; ovarian, breast, lung, GU, GI, othersolidChemotherapy, platinum & non platinumHb ≤ 11 g/dl OR ≤ 13 g/dl AND decrease of ≥1.5 g/dL per CT cyclemedian 9.6median 10.31052, range 20–8557, range 19–73adults
O’Shaughnessy 2005 100breast cancer, stages I-IIIBsolidChemotherapy without platinumHb 9–14 g/dl12.8 (SD 1.0)13.0 (SD 1.0)1253.3 (SD 9.7)54.3 (SD 12.0)adults
Osterborg 1996 a,b144MM, NHL, CLLhematologicalChemotherapy without platinum, 6/59 (10%) did not receive chemotherapy, study categorized as chemotherapy non platinum categoryHb ≤ 10 g/dla: median 8.0 (range 6.2–10.1), b: median 8.0 (range 5.5–10.3)median 8.1 (range 5.2–9.8)10a: 66(43–84), b: 65 (38–82)64 (36–83)adults
Osterborg 2002, Osterborg 2005349MM, NHL, CLLhematologicalChemotherapy without platinumHb ≤ 10 g/dl9.2 (SD 1.1)9.3 (SD 1.0)1063 (32–86)64 (28–83)adults
P-17445CLLhematologicalChemotherapy (NR, but for some patients reported in Pangalis 1995), categorized as ‘unclear’Hct < 32%NRNRNR (no assumption possible)NRadults
Quirt 1996 56lymphoma, solid tumoursmixedChemotherapy, unclear if platinum included or not, categorized as ‘unclear’ OKHb drop of 1.5 g/dL10.910.710–12NRNRadults
Razzouk 2004 224solid tumours, Hodgkin’s disease, non-Hodgkin’s disease, ALLmixedChemotherapy
’unclear’
Hb ≤ 12 g/dl9.8 (SD 1.3)9.5 (SD 1.0)1012.4 (SD 3.6)10.8 (SD 4.0)children
Rose 1994 221CLL, stage III, IVhematologicalChemotherapy (only 162/221 (73%) received CT), categorized as chemotherapy without platinumHct ≤ 32%9.1 (1.3)9.3 (1.2)1068.3 (SD 10)68.1 (9.3)adults
Rosenzweig 2004 27metastatic breast cancersolidChemotherapy, 14/27 (52%) did not receive chemotherapy, categorized as ‘unclear’Hb <12g/dLNRNRNR (no assumption possible)55.9 (+/−11.7)53.9 (+/− 14.2)adults
Savonije 2004 315solid tumorssolidPlatinum based chemotherapyHb <12.1 g/dL10.7 (SD 1.0)10.8 (SD 1.0)10–1256.9 (SD 10.9)57.7 (SD 9.5)adults
Silvestris 1995 54MMhematologicalChemotherapyHb 8 ≤ g/dlNRNRNR (no assumption possible)NRadultsadults
Ten Bokkel 1998 a, b122ovarian (stage II-IV)solidPlatinum based chemotherapyHb ≤ 13 g/dla: 12.0 (1.3–12.6, SD 0.88), b:11.6 (10.5–12.2, SD 1.34)11.8 (10.6–12.5, SD 1.19)10–12a: 58.81, b: 60.9758.83adults
Thatcher 1999 a, b130SCLCsolidPlatinum based chemotherapy (89% of patients)Hb ≥ 10.5 g/dla: 13.4 (SD 1.3), b: 13.5 (SD 1.3)13.4 (SD 1.3)12a: 59 (43–72), b: 58.5 (30–72)60 (39–74)adults
Thomas 2002 130NRunclearChemotherapy, categorized as ‘unclear’(Hb inclusion criteria level: < 12g/dL)10.59 (SD 1.05)10.59 (SD 1.05)10–12NRNRadults
Throuvalas 2000 55cervix and bladder carcinomasolidPlatinum based chemotherapy plus radiotherapy, categorized as chemo_radio therapyHb 10–13 g/dl11.5 (SD 0.6)11.1 (0.5)10–1254 (36–75)58 (35–75)adults
Vadhan-Raj 2004 60gastric or rectal casolidcombined chemo-radio therapy without platinum, categorized as chemo_radioHb 10–15 g/dlmedian 13median 1312NRNRadults
Welch 1995 30ovarian, stage II-IVsolidPlatinum based chemotherapynormal Hb1312.812NRNRadults
Witzig 2005344lung, breast, othersolidChemotherapy, platinum & non platinum, some radiotherapy, 56/330 (175) received platinumHb ≤ 11.5 g/dl (men), Hb ≤ 10.5 g/dl (women)9.5, range 6.0–11.49.4, range 6.9–11.41063.6 (SD 11.89), range 20–8863.7 (SD 13.00), range 24–86adults
Wurnig 1996 30various malignant one tumourssolidChemotherapy, platinum & non platinum, 21/35 (60%) received platinumHb 11 g/dl11.0 (SD 1.5)10.5 (SD 0.75)10–12NRNRadults

From: Appendix C, Evidence Tables

Cover of Comparative Effectiveness of Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment
Comparative Effectiveness of Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment [Internet].
Comparative Effectiveness Reviews, No. 3.
Seidenfeld J, Piper M, Bohlius J, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.